Clinomic Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 75

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $25M

  • Investors
  • 7

Clinomic General Information

Description

Developer of a medical software platform designed to manage electronic health records systems and analyze patient data. The company's platform leverages artificial intelligence and clinical data to provide clinicians with real-time insights and decision support tools, enabling healthcare providers in intensive care units to optimize treatment plans and improve patient outcomes.

Contact Information

Website
www.clinomic.ai
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Jülicher Straße 306
  • 52070 Aachen
  • Germany
+49 0241
Primary Industry
Other Healthcare Technology Systems
Corporate Office
  • Jülicher Straße 306
  • 52070 Aachen
  • Germany
+49 0241

Clinomic Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Clinomic Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 08-Apr-2025 $25M Completed Generating Revenue
6. Accelerator/Incubator 25-Feb-2025 Completed Generating Revenue
5. Early Stage VC 01-Jul-2023 Completed Generating Revenue
4. Early Stage VC 19-Mar-2021 Completed Generating Revenue
3. Accelerator/Incubator Completed Generating Revenue
2. Grant 01-Nov-2019 $55.3K Completed Startup
1. Accelerator/Incubator 23-May-2019 Completed Startup
To view Clinomic’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Clinomic Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Clinomic Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
DeepTech & Climate Fonds Venture Capital Minority
Scale Up.NRW Accelerator/Incubator
Sana Kliniken Corporation Minority
Bundesministerium für Bildung und Forschung Government Minority
EIT Health Accelerator/Incubator
You’re viewing 5 of 7 investors. Get the full list »

Clinomic FAQs

  • When was Clinomic founded?

    Clinomic was founded in 2019.

  • Where is Clinomic headquartered?

    Clinomic is headquartered in Aachen, Germany.

  • What is the size of Clinomic?

    Clinomic has 75 total employees.

  • What industry is Clinomic in?

    Clinomic’s primary industry is Other Healthcare Technology Systems.

  • Is Clinomic a private or public company?

    Clinomic is a Private company.

  • What is Clinomic’s current revenue?

    The current revenue for Clinomic is .

  • How much funding has Clinomic raised over time?

    Clinomic has raised $50.8M.

  • Who are Clinomic’s investors?

    DeepTech & Climate Fonds, Scale Up.NRW, Sana Kliniken, Bundesministerium für Bildung und Forschung, and EIT Health are 5 of 7 investors who have invested in Clinomic.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process